ClinicalTrials.gg
Enrolling by invitationNCT05725759Updated Nov 9, 2026

Rehabilitation and Exercise in SOD1-ALS TOfersen REcipients (RESTORE)

An observational study in Amyotrophic Lateral Sclerosis, Lou Gehrig Disease and Familial Amyotrophic Lateral Sclerosis, sponsored by Washington University School of Medicine. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Washington University School of Medicine · Observational

How we know

Updated Nov 9, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
110th of 121
10 · median 100
Started
2022
with 18 others
Observational
121 of 440
34 open now
Primary completion
2027-12
later than 72 of 128 live
Registered
335th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 110th largest by planned enrollment of the 121 observational ones that give a count, is one of 19 that started in 2022, is one of 121 observational ones, reaches primary completion later than 72 of the 128 other live ones, and was the 335th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program. Participants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy. Participants will have an initial assessment performed and an individualized rehabilitation program will be prescribed. Each participant is encouraged to follow the prescribed recommendations that will include scheduled outpatient therapy sessions, functional assessments, and/or a home-based rehabilitation program. Functional assessments will be done at a minimum of every three months.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Lou Gehrig Disease
  • Familial Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease
  • Motor Neuron Disease, Familial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with SOD1 ALS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of ALS with an SOD1 mutation
  • Current enrollment in the tofersen expanded access program
  • Age greater than 18 years
  • Medically able to participate in outpatient physical therapy and/or home-based rehabilitation, as determined by the treating health care provider

Exclusion criteria

Exclusion Criteria:

  • Any comorbidities or conditions that, in the opinion of the treating healthcare provider, would unacceptably increase the risk of participation in outpatient physical therapy and/or home-based rehabilitation
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rehabilitation Arm

    Participants will participate in outpatient physical and/or occupational therapies while participating in the tofersen early access program (EAP)

    Behavioral: Rehabilitation

Interventions

  • BehavioralRehabilitation

    Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.

    Also known as: physical therapy, occupational therapy

06

What researchers measure

Primary outcomes

  1. Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS)

    ALSFRS-R measures functional disease severity in four functional domains, bulbar function, gross motor skills, fine motor skills, and respiratory. The assessment contains 12 questions scored from 0 (no function) to 4 (full function), with a total possible score of 48, which will indicate the highest level of function.

    Time frame: 12 months

Secondary outcomes

  1. 1. Change from baseline in Handheld Dynamometry (HHD)

    Quantitative muscle strength will be evaluated using HHD of multiple muscles using standard participant positioning.

    Time frame: 12 months

  2. 2. Change from baseline in Rasch-Built Overall Amyotrophic Lateral Sclerosis Functional Rating (ROADS)

    ROADS measures disability across multiple daily activities. For each question, response options are as follows: 0=unable to perform; 1=abnormal, able to perform but with difficulty; and 2=normal, able to perform without difficulty.

    Time frame: 12 months

  3. 3. Change from baseline in ALS Assessment Questionnaire, 5-item (ALSAQ-5)

    Quality of life will be measured using the 5-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5) patient-reported outcome (PRO)

    Time frame: 12 months

  4. Change from baseline in motor Functional Independence Measure (motor FIM)

    Measures level of disability and indicates level of assistance required to perform activities of daily living.

    Time frame: 12 months

  5. Change from baseline in Modified Ashworth Scale (MAS)

    The MAS is 6-point scale that that grades spasticity, scored from 0 to 4, where 0 is normal muscle tone and 4 is severe increase in muscle tone

    Time frame: 12 months

  6. Change from baseline in Slow Vital Capacity (SVC)

    Time frame: 12 months

  7. Change from baseline in Maximal Inspiratory Pressure (MIP)

    Time frame: 12 months

  8. Change from baseline in Fatigue Severity Scale (FSS)

    FSS measures how fatigue interferes with activities. It is a 9-item questionnaire scored on a 7-point scale, 1 = strongly disagree to 7 = strongly agree, and the higher the score equal to the greater the severity of fatigue

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 61 months is close to that.

Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2024 → Dec 2027 and completion Dec 2024 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 13, 2023
StartActual
Nov 8, 2022
Primary completionEst.
Dec 2027was Dec 2024
CompletionEst.
Dec 2027was Dec 2024
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Washington University School of Medicine · St Louis, United States
Show 1 removed
  • Washington University School of Medicine · Saint Louis, United States
Nov 9, 2026
Primary completion
Dec 2024→Dec 2027
Nov 9, 2026
Study completion
Dec 2024→Dec 2027
Nov 9, 2026
Title
Rehabilitation and Exercise in SOD1 -ALS Treated With TofersenTOfersen REcipients (RESTORE)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added, 1 site removed
    Show site
    • Washington University School of Medicine · St Louis, United States
    Show 1 removed
    • Washington University School of Medicine · Saint Louis, United States
    Primary completion Dec 2024→Dec 2027
    Study completion Dec 2024→Dec 2027
    Title Rehabilitation and Exercise in SOD1 -ALS Treated With TofersenTOfersen REcipients (RESTORE)
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05725759
Responsible party
Sean E Smith (Instructor in Neurology, Washington University School of Medicine) — Principal investigator
First posted
Feb 13, 2023
Start date
Nov 8, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion